After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
Agios' Rare Anemia Drug Application Under FDA Priority Review
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
Sanofi's Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA Rejection
Anemia Recent News
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
Silence Therapeutics' siRNA Candidate Reduces Plasma Iron Levels, Early-Stage Study Shows
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
Bristol-Myers, Acceleron's Reblozyl Ok'd In Canada For MDS-Associated Anemia
Keryx Biopharmaceuticals Surges 20% Following Positive Kidney Disease Drug Data